Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.44 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 5/20 | 0.41 |
| ▸ | NPY4R | P50391 | 5/20 | 0.40 |
| ▸ | NPY1R | P25929 | 4/20 | 0.40 |
| ▸ | NPY2R | P49146 | 4/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29476475 | 0.99 | FOLH1 (0.45) | FOLH1APLNRMC4RNPY4RNPY1R | |
| SCHEMBL30044979 | 0.94 | NPY4R (0.42) | APLNRMC4RNPY4RNPY1RNPY2R | |
| SCHEMBL31620054 | 0.94 | FOLH1 (0.45) | FOLH1APLNRMC4RCTNNB1 | |
| SCHEMBL30510368 | 0.93 | NPY4R (0.44) | APLNRMC4RNPY4RNPY1RNPY2R | |
| SCHEMBL30663358 | 0.92 | FOLH1 (0.46) | FOLH1MC4RNPY4RNPY1RNPY2R | |
| SCHEMBL29511079 | 0.91 | NPY4R (0.44) | APLNRMC4RNPY4RNPY1RNPY2R | |
| SCHEMBL30510396 | 0.91 | MC4R (0.50) | MC4R | |
| SCHEMBL29511116 | 0.91 | FNTA (0.47) | FOLH1APLNRMC4RNPY4RNPY1R | |
| SCHEMBL29476385 | 0.91 | NPY4R (0.43) | APLNRMC4RNPY4RNPY1RNPY2R | |
| SCHEMBL30510278 | 0.90 | NPY4R (0.44) | APLNRMC4RNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195606-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2025-06-19 | — | — | US | disclosed |
| EP-4554607-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20240058414-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2024015880-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240058414-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | FOLH1 1460/4885APLNR 177/4885MC4R 1/4885 |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | FOLH1 1148/4885APLNR 50/4885MC4R 1/4885 |
| US-20250195606-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | FOLH1 1434/4885APLNR 685/4885MC4R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.